# US 2006/0188984 A1 · Method of providing readily available cellular material derived from cord blood, and a composition thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0188984 A1
- Document ID: US20060188984A1
- Status: Published application
- Kind: A1
- Application number: 11/340,114
- Filed: 2006-01-26
- Published: 2006-08-24
- Earliest claimed: 2005-01-27
- Inventors: Donnie Rudd
- Web page: https://patentgrep.com/patent/US20060188984A1

## CPC

- A01N 1/10: Preservation of living parts
- A01N 1/125: Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 41/0052: {Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- C12M 27/10: {Rotating vessel}
- C12M 35/02: {Electrical or electromagnetic means, e.g. for electroporation or for cell fusion}
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 2529/00: Culture process characterised by the use of electromagnetic stimulation
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is directed to the TVEMF-expansion of mammalian cord blood stem cells, preferably CD34+/CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating disease or repairing tissue with the compositions. Various benefits and advantages to the compositions of the present invention are discussed herein.

## Claims

### Claim 1

Cord blood stem cells from a mammal,
wherein said cord blood stem cells are in a number per volume that is at least 7 times greater than naturally-occurring cord blood; and
wherein the cord blood stem cells have a three-dimensional geometry and cell-to-cell support and cell-to-cell geometry that is essentially the same as stem cells of naturally-occurring cord blood.

### Claim 2 (depends on 1)

A composition comprising the cord blood stem cells of claim 1 and an acceptable carrier.

### Claim 3 (depends on 2)

A composition of claim 2, wherein said acceptable carrier is at least one of the group consisting of plasma, blood, albumin, cell culture medium, growth factor, copper chelating agent, hormone, buffer and cryopreservative.

### Claim 4 (depends on 3)

The composition of claim 3, wherein said growth factor is G-CSF.

### Claim 5 (depends on 2)

The composition of claim 2, wherein said composition is at a temperature sufficient to cryogenically preserve the cord blood stem cells.

### Claim 6 (depends on 2)

The composition according to claim 2, wherein a cryopreservative is present in an amount sufficient for cryopreservation of said cells, and wherein said composition is at a temperature of from about −120° C. to about −196° C.

### Claim 7 (depends on 6)

The composition according to claim 6, wherein said temperature is from about −130° C. to about −150° C.

### Claim 8 (depends on 6)

The composition according to claim 6, further comprising a pharmaceutically acceptable carrier.

### Claim 9 (depends on 3)

The composition according to claim 3, wherein said composition comprises a cryopreservative selected from the group consisting of 20 to 40% dimethyl sulfoxide solution in 60 to 80% amino acid-glucose solution; 15 to 25% hydroxyethyl starch solution; 4 to 6% glycerol, 3 to 5% glucose and 6 to 10% dextran T10; 15 to 25% polyethylene glycol; and 75 to 85% amino acid-glucose solution.

### Claim 10 (depends on 2)

The composition of claim 2, wherein said composition is free of toxic material.

### Claim 11

Cord blood stem cells from a mammal, wherein said cord blood stem cells are TVEMF-expanded.

### Claim 12 (depends on 11)

The TVEMF-expanded cord blood stem cells of claim 11, wherein the number of TVEMF-expanded cord blood stem cells per volume is at least 2 times greater than the number of stem cells per volume of the cord blood from which the TVEMF-expanded cord blood stem cells are derived.

### Claim 13 (depends on 12)

The TVEMF-expanded cord blood stem cells of claim 12, wherein the number of TVEMF-expanded cord blood stem cells per volume is at least 7 times greater.

### Claim 14 (depends on 13)

A composition comprising the cord blood stem cells of claim 13 and an acceptable carrier.

### Claim 15 (depends on 13)

A composition comprising the TVEMF-expanded cord blood stem cells of claim 13 wherein said composition further comprises at least one of the group consisting of plasma, blood, albumin, cell culture medium, growth factor, copper chelating agent, hormone, buffer and cryopreservative.

### Claim 16 (depends on 15)

The composition of claim 15, wherein said growth factor is G-CSF.

### Claim 17 (depends on 14)

The composition according to claim 14, wherein said composition further comprises cryopreservative selected from the group consisting of 20 to 40% dimethyl sulfoxide solution in 60 to 80% amino acid-glucose solution; 15 to 25% hydroxyethyl starch solution; 4 to 6% glycerol, 3 to 5% glucose and 6 to 10% dextran T10; 15 to 25% polyethylene glycol; and 75 to 85% amino acid-glucose solution.

### Claim 18 (depends on 14)

The composition of claim 14, wherein said composition is at a temperature sufficient to cryogenically preserve the cord blood stem cells.

### Claim 19 (depends on 14)

The composition according to claim 14, wherein a cryopreservative is present and wherein said composition is at a temperature of from about −120° C. to about −196° C.

### Claim 20 (depends on 14)

The composition according to claim 14, wherein said temperature is from about −130° C. to about −150° C.

### Claim 21 (depends on 14)

The composition of claim 14, wherein said composition is free of toxic material.

### Claim 22

A process for preparing a cord blood stem cell composition comprising the steps of:
a. placing a cord blood mixture in a culture chamber of a TVEMF-bioreactor; and
b. subjecting the cord blood mixture to a TVEMF and TVEMF-expanding the cord blood stem cells to prepare the cord blood stem cell composition.

### Claim 23 (depends on 22)

The process according to claim 22, wherein said TVEMF is about 0.05 to about 6.0 gauss.

### Claim 24 (depends on 22)

The process according to claim 22, wherein said TVEMF-expanding continues until the number per volume of TVEMF-expanded cord blood stem cells is more than 7 times the number per volume of cord blood stem cells placed in the TVEMF-bioreactor.

### Claim 25 (depends on 22)

The process according to claim 22, further comprising collecting cord blood from a mammal prior to placing the cord blood mixture in a TVEMF-bioreactor.

### Claim 26 (depends on 25)

The process of claim 25, wherein said mammal is human.

### Claim 27 (depends on 22)

The process according to claim 22, further comprising collecting thawed cryopreserved cord blood from a cord blood storage facility prior to adding the cord blood to the cord blood mixture.

### Claim 28 (depends on 22)

The process of claim 22, further comprising a step of removing toxic material from the cord blood mixture prior to TVEMF-expansion.

### Claim 29 (depends on 22)

The process of claim 22, wherein the TVEMF-bioreactor has an integral TVEMF source.

### Claim 30 (depends on 22)

The process of claim 22, wherein the TVEMF-bioreactor has an adjacent TVEMF source.

### Claim 31 (depends on 22)

The process of claim 22, wherein the cord blood mixture comprises CD34+/CD38− cord blood stem cells separated from other cord blood components.

### Claim 32 (depends on 22)

The process of claim 22, wherein the cord blood mixture comprises a buffy coat separated from other cord blood components.

### Claim 33 (depends on 22)

The process of claim 22, wherein the cord blood mixture comprises cord blood free of red blood cells.

### Claim 34 (depends on 22)

The process of claim 22, further comprising the steps of transferring the TVEMF-expanded cells of the cord blood stem cell composition into a cryogenic container having a temperature, and lowering the temperature of the cryogenic container to a temperature of from −120° C. to −196° C. at a controlled rate.

### Claim 35 (depends on 34)

The process of claim 34, further comprising a step of removing toxic material from the cord blood stem cell composition prior to lowering the temperature to a temperature of from −120° C. to −196° C. at a controlled rate.

### Claim 36 (depends on 34)

The process of claim 34, further comprising, after the step of lowering the temperature, a step of maintaining the temperature of the cryogenic container to a temperature of from −120° C. to −196° C., for a period of time.

### Claim 37 (depends on 36)

The process of claim 36, wherein said period of time is at least 1 year.

### Claim 38 (depends on 36)

The process of claim 36, further comprising, after said lowering and maintaining of temperature, a step of increasing the temperature of the cryogenic container at a controlled rate to a temperature suitable for introducing the cord blood stem cell composition to a mammal.

### Claim 39 (depends on 38)

The process of claim 38, wherein toxic material has been removed from said increased temperature cord blood stem cell composition.

### Claim 40 (depends on 34)

The process of claim 34, further comprising the step of adding a cryopreservative to the TVEMF-expanded cells of the cord blood stem cell composition.

### Claim 41 (depends on 22)

A composition comprising cord blood stem cells and an acceptable carrier prepared by the process according to claim 22.

### Claim 42 (depends on 1)

A method of repairing tissue of a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the cord blood stem cells of claim 1 and a pharmaceutically acceptable carrier.

### Claim 43 (depends on 11)

A method of repairing tissue of a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the TVEMF-expanded cord blood stem cells of claim 11 and a pharmaceutically acceptable carrier.

### Claim 44 (depends on 43)

The method of claim 43, wherein the tissue to be repaired is human tissue.

### Claim 45 (depends on 44)

The method of claim 44, wherein the tissue to be repaired is a vital organ.

### Claim 46 (depends on 44)

The method of claim 44, wherein the tissue to be repaired is at least one selected from the group consisting of a liver tissue, heart tissue, hematopoietic tissue, blood vessels, skin tissue, muscle tissue, gut tissue, pancreatic tissue, central nervous system cells, bone, cartilage tissue, connective tissue, pulmonary tissue, spleen tissue and brain tissue.

### Claim 47 (depends on 43)

The method of claim 43, wherein the amount of TVEMF-expanded cord blood stem cells to be administered to the mammal is at least 20 ml of a composition having 107 to 109 stem cells/ml.

### Claim 48 (depends on 1)

A method of treating a disease of a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the cord blood stem cells of claim 1 and a pharmaceutically acceptable carrier.

### Claim 49 (depends on 11)

A method of treating a disease of a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the TVEMF-expanded cord blood stem cells of claim 11 and a pharmaceutically acceptable carrier.

### Claim 50 (depends on 49)

The method of claim 49, wherein the tissue to be repaired is human tissue.

### Claim 51 (depends on 50)

The method of claim 50, wherein the tissue to be repaired is a vital organ.

### Claim 52 (depends on 50)

The method of claim 50, wherein the tissue to be repaired is at least one selected from the group consisting of a liver tissue, heart tissue, hematopoietic tissue, blood vessels, skin tissue, muscle tissue, gut tissue, pancreatic tissue, central nervous system cells, bone, cartilage tissue, connective tissue, pulmonary tissue, spleen tissue and brain tissue.

### Claim 53 (depends on 49)

The method of claim 49, wherein the amount of TVEMF-expanded cord blood stem cells to be administered to the mammal is at least 20 ml of a composition having 107 to 109 stem cells/ml.
